Acrux Limited and Amring Pharmaceuticals Inc. have mutually agreed to terminate the agreement for the development and commercialisation of a generic topical product for the United States market. Acrux retains exclusive ownership of all rights and Intellectual Property associated with the Product. The Product is at an advanced stage of development and the company's target is to submit the Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) in late 2023.

Acrux is seeking to appoint a commercial licensing partner to launch the product after receipt of the necessary approvals from FDA.